SCHEMBL5207975

SCHEMBL5207975

CN1CCC(CN2CCN(C(=O)CCc3oc(-c4n[nH]c5ccccc45)nc3-c3ccc(Cl)cc3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 9/20 0.45
CACNA2D1 P54289 1/20 0.41
CACNA1B Q00975 1/20 0.41
CACNB1 Q02641 1/20 0.41
CACNA1C Q13936 1/20 0.41
POLB P06746 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
FASN P49327 3/20 0.39
TNKS O95271 1/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.35
MAPK1 P28482 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211972 0.86 TNKS (0.42) TACR1FASNTNKSPARP1PARP2
SCHEMBL5212036 0.86 TACR1 (0.46) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5210242 0.84 TACR1 (0.47) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5214208 0.84 TACR1 (0.46) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5213743 0.83 TACR1 (0.49) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5212616 0.82 TACR1 (0.45) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5207901 0.81 CACNA2D1 (0.46) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5212688 0.81 TACR1 (0.50) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
Hydrochloric Acid SCHEMBL5209960 0.80 TACR1 (0.49) TACR1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5210084 0.80 TACR1 (0.46) TACR1CACNA2D1CACNA1BCACNB1CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 TACR1 2372/4885CACNA2D1 4406/4885CACNA1B 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.